Kailera Therapeutics, Inc. (KLRA) Stock Forecast
KLRA analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.83 / 5 from 6 analysts
- Price target
- $42.40 average of analyst targets
- Upside to target
- +276.9% from the latest close
- Next earnings
- November 11, 2026 EPS estimate $-1.55
- 52-week range
- $10.00 – $26.00
KLRA analyst ratings
6 analystsNumber of analysts at each rating.
KLRA price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
KLRA earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.01 | −$1.30 | −$0.79 | — | — | 5 |
| Current fiscal year (2026) | −$4.10 | −$5.86 | −$2.96 | — | — | 5 |
| Next fiscal year (2027) | −$4.30 | −$5.89 | −$2.99 | −$4.10 | −4.9% | 5 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
KLRA revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | — | 6 |
| Current fiscal year (2026) | $0 | $0 | $0 | — | 6 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 6 |
KLRA EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
KLRA EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.93 | −$0.93 | −$1.06 | −$1.01 | −$1.01 | +9.2% | 1 up · 1 down |
| Current fiscal year (2026) | −$3.97 | −$3.97 | −$4.38 | −$4.10 | −$4.10 | +3.2% | 0 up · 2 down |
| Next fiscal year (2027) | −$4.10 | −$4.10 | −$4.30 | −$4.30 | −$4.30 | +4.9% | 1 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
KLRA earnings surprises
Reported EPS vs the consensus estimate for the last 2 quarters; KLRA beat in 0 of 2.
What analysts expect from KLRA
6 analysts cover Kailera Therapeutics; their consensus rating is strong buy (4.83 on a 1–5 scale, where 5 is a strong buy). The average price target is $42.40, 276.9% above the latest close of $11.25. Analysts expect earnings of −$4.10 per share for 2026. For 2027 the average estimate is −$4.30 per share. Kailera Therapeutics beat the EPS estimate in 0 of the last 2 quarters.
Related: KLRA income statement, KLRA chart. See the KLRA stock overview for the latest quote and news.
KLRA forecast FAQ
What is Kailera Therapeutics's price target?
The average analyst price target for Kailera Therapeutics is $42.40, 276.9% above the latest close of $11.25.
Is Kailera Therapeutics a buy, hold or sell?
Of 6 analysts covering Kailera Therapeutics, 5 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Kailera Therapeutics's EPS forecast?
Analysts forecast −$4.10 per share for 2026 (range −$5.86 to −$2.96); for 2027 the estimate is −$4.30.
When does Kailera Therapeutics report earnings?
Kailera Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 11, 2026; the EPS estimate is $-1.55.
Does Kailera Therapeutics usually beat earnings estimates?
Kailera Therapeutics reported EPS at or above the analyst estimate in 0 of the last 2 quarters.